Today: 4 July 2026
Browse Category

NASDAQ:HOLX 21 October 2025 - 9 April 2026

Hologic goes private: Blackstone, TPG close buyout and name José Almeida CEO

Hologic goes private: Blackstone, TPG close buyout and name José Almeida CEO

Hologic is no longer public. The company wrapped up its sale to Blackstone and TPG, with the women’s health and diagnostics firm now in private-equity hands—José Almeida, previously at Baxter, will take the helm. Equityholders are getting about $17.3 billion in cash, according to an April 7 filing. This close means a familiar medtech player disappears from both Nasdaq and the S&P 500. S&P Dow Jones is set to drop Hologic from the index before trading starts Thursday. Reuters called the October deal one of the largest medical-device transactions in nearly 20 years.
9 April 2026
··
Hologic Buyout Nears Close After Final Approvals in Blackstone-TPG Deal; CEO Steve MacMillan to Retire

Hologic Buyout Nears Close After Final Approvals in Blackstone-TPG Deal; CEO Steve MacMillan to Retire

MARLBOROUGH, Mass., April 7, 2026, 07:07 EDT Hologic has locked in all the necessary regulatory sign-offs for its sale to Blackstone and TPG, with the $18.3 billion take-private transaction on track to wrap up around April 7. Chairman, President and CEO Steve MacMillan—who has led the company for years—will step down following the close, he confirmed.
7 April 2026
··
Hologic stock (HOLX) after-hours on Dec. 24, 2025: CVR milestone risk, Blackstone–TPG deal spread, and what to watch before the next market open

Hologic stock (HOLX) after-hours on Dec. 24, 2025: CVR milestone risk, Blackstone–TPG deal spread, and what to watch before the next market open

Dec. 24, 2025 — Hologic, Inc. finished the shortened Christmas Eve session at $74.50, with the stock trading around $74.80 in after-hours activity as of 7:00 p.m. ET. StockAnalysis+1 While today’s tape was shaped by holiday-thinned liquidity and an early close, the more important driver for HOLX right now is deal math — and fresh scrutiny around whether Hologic’s Breast Health revenue can still clear the targets tied to its contingent value right.
24 December 2025
Blackstone (BX) Shines With Big Q3 Beat & $18B Hologic Deal – But Why Are Shares Falling?

Blackstone (BX) Shines With Big Q3 Beat & $18B Hologic Deal – But Why Are Shares Falling?

Blackstone’s latest results painted a mixed picture. The firm reported distributable earnings of $1.889 billion, up 48% from a year ago and well above the $1.23 forecastreuters.com. However, on a GAAP basis net income dropped to $624.9 million from $780.8 million last year, and total revenue slid about 15.7% year-over-yearts2.tech. Investors focused on the earnings miss and slowing revenue, which partly offset the beat on cash profit. As a result, BX shares dipped about 1% intraday on Oct. 23, trading around $160benzinga.com. CEO Steve Schwarzman nonetheless called Q3 “exceptional” due to momentum across Blackstone’s businessesbenzinga.com. Piper Sandler analyst Crispin Love said the better-than-expected results were driven by a surge in realized performance fees – reflecting renewed deal activity – after a multi‑year lull. “There’s been a lot of pent-up demand… and you’re beginning to see that come through,” Love said, adding that this sets up 2026 for a potential boom in IPOs and exitsreuters.com. Indeed, Blackstone sold roughly $30 billion of investments in Q3, more than doubling its PE segment earnings from the prior quarterreuters.com. Meanwhile, its credit and insurance arm continued to attract huge capital: $54.2 billion of new inflows in Q3 lifted Blackstone’s total assets under management to
23 October 2025
···
Blackstone & TPG in $18B Hologic Takeover Shock – Women’s Health Stock Skyrockets

Blackstone & TPG in $18B Hologic Takeover Shock – Women’s Health Stock Skyrockets

Hologic is a Marlborough, MA–based medical technology firm focused on women’s health. Its products include mammography and breast biopsy systems, cervical cancer tests, surgical equipment, and lab diagnostics including molecular tests for Covid-19 bostonglobe.com. The Blackstone/TPG consortium will buy all outstanding Hologic shares for $76 cash plus a $3 CVR marketscreener.com. This values the deal at $79 per share maximum and around $18.3 billion total enterprise value marketscreener.com. The purchase price represents a roughly 46% premium to Hologic’s share price before takeover rumors marketscreener.com. The agreement includes minority co-investments by ADIA and GIC, reflecting confidence from large sovereign investors. Goldman Sachs advised Hologic, while Citi and Bank of America advised Blackstone/TPG marketscreener.com. The transaction is expected to close in the first half of 2026, subject to approval by Hologic shareholders and regulators marketscreener.com. The Hologic board has unanimously recommended shareholders approve the merger agreement marketscreener.com. Following closing, Hologic will be delisted from Nasdaq and go private, though it will continue operating under the Hologic name with its Boston-area headquarters preserved marketscreener.com.
21 October 2025
····

Stock Market Today

  • Marvell Drops Almost 10% as AI Data-Center Worries Hit Stock
    July 3, 2026, 7:51 PM EDT. Marvell Technology (NASDAQ:MRVL) sank 9.84% to $245.29, erasing about $23.4 billion in value, more than triple its annualized data-center revenue in just one session. Data-center sales make up 76% of total revenue, leaving Marvell exposed to any cuts in AI infrastructure spending. Losses were deeper than rivals like NVIDIA, Broadcom, AMD, and Micron. President Chris Koopmans sold a small personal stake recently, though it was only a sliver of the outstanding shares. Investors grew wary of AI spending and data-center capex, sending Marvell sharply lower ahead of the July 4th holiday. The Nasdaq Composite dropped 0.8%. Marvell now trades at about 29.3 times annualized Q1 data-center revenue.
Go toTop